Abstract
Insufficient HIV drug levels in lymph nodes have been linked to viral persistence. To overcome lymphatic drug insufficiency, we developed and evaluated in primates a lipid-drug nanoparticle containing lopinavir, ritonavir, and tenofovir. These nanoparticles produced over 50-fold higher intracellular lopinavir, ritonavir and tenofovir concentrations in lymph nodes compared to free drug. Plasma and intracellular drug levels in blood were enhanced and sustained for 7 days after a single subcutaneous dose, exceeding that achievable with current oral therapy.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives
-
Adenine / pharmacokinetics
-
Animals
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / pharmacokinetics*
-
Blood Cells / chemistry*
-
Drug Carriers / administration & dosage
-
Drug Combinations
-
Lopinavir / administration & dosage
-
Lopinavir / pharmacokinetics
-
Lymph Nodes / chemistry*
-
Macaca nemestrina
-
Nanoparticles / administration & dosage*
-
Organophosphonates / administration & dosage
-
Organophosphonates / pharmacokinetics
-
Plasma / chemistry*
-
Ritonavir / administration & dosage
-
Ritonavir / pharmacokinetics
-
Tenofovir
Substances
-
Anti-HIV Agents
-
Drug Carriers
-
Drug Combinations
-
Organophosphonates
-
Lopinavir
-
Tenofovir
-
Adenine
-
Ritonavir